In examining the protein levels of Cldn3 and Cldn4 after 72 h, we generated a knocked down of greater than or equal to 70% for both PC3 and LNCaP human prostate cancer cells when treated with siCldn3s and siCldn4s (Fig. 2c). The gene discussed is CLDN3; the disease is prostate cancer.